/ADMP

ADMP Stock - Adamis Pharmaceuticals Corporation

Q: What is the analyst price target for ADMP?

Analyst price target information is not currently available for ADMP.

Q: What is ADMP's market cap?

Market capitalization information is not currently available for ADMP.

Healthcare|Drug Manufacturers - Specialty & Generic|NASDAQ

$0.78+0.85%

+$0.01 (+0.85%) • Sep 7

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $0.85

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for ADMP

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2018

FY2019

FY2020

FY2021

FY2022

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta1.28

52W High$21.70

52W Low$0.45

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2022	FY2021	FY2020	FY2019	FY2018
Revenue	$4.76M	$2.21M	$16.53M	$22.11M	$15.09M
Gross Profit	$-1,431,408	$-4,663,451	$1.63M	$6.64M	$5.29M
Gross Margin	-30.1%	-211.1%	9.9%	30.0%	35.1%
Operating Income	$-25,058,966	$-32,069,409	$-37,227,915	$-29,028,505	$-39,463,760
Net Income	$-26,199,406	$-34,600,353	$-49,391,089	$-29,306,769	$-39,006,782
Net Margin	-550.9%	-1566.6%	-298.8%	-132.5%	-258.6%
EPS	$-12.24	$-16.80	$-44.57	$-38.52	$-69.86

Company Overview

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease in the United States. The company's product candidates comprise SYMJEPI epinephrine pre-filled syringe injectable products for use in the emergency treatment of acute allergic reactions, including anaphylaxis; dry powder inhaler products for the treatment of asthma; and naloxone injection for the treatment of opioid overdose. It also offers APC400, a tempol gel use of reducing radiation dermatitis in patients undergoing treatment for cancer; and APC410 for the treatment of respiratory diseases, including asthma, respiratory syncytial virus, influenza, and COVID-19. In addition, the company provides corticosteroids, hormone replacement therapies, hospital outsourcing products, and injectables; and veterinary pharmaceutical products for animals. Adamis Pharmaceuticals Corporation was founded in 2006 and is headquartered in San Diego, California.

Visit Website

Earnings History & Surprises

ADMP

Beat Rate

80%

Last 10 quarters

Avg Surprise

-649.5%

EPS vs Estimate

Beats / Misses

8/2

Last 12 quarters

Latest EPS

$2.79

Q3 2023

EPS Surprise History

Q4 21

-50.0%

$2.10vs$4.20

Q1 22

+33.3%

$0.06vs$0.04

Q2 22

+133.3%

$4.90vs$2.10

Q3 22

+50.0%

$4.20vs$2.80

Q4 22

No data

Q1 23

No data

Q2 23

No data

Q3 23

No data

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q3 2024	Aug 19, 2024	—	—	—	—
Q2 2024	May 13, 2024	—	—	—	—
Q1 2024	Mar 14, 2024	—	—	—	—
Q4 2023	Nov 13, 2023	—	—	—	—
Q3 2023	Aug 21, 2023	—	$2.79	—	—
Q2 2023	May 15, 2023	—	$4.20	—	—
Q1 2023	Mar 16, 2023	—	$0.02	—	—
Q4 2022	Nov 28, 2022	—	$0.03	—	—
Q3 2022	Aug 10, 2022	$2.80	$4.20	+50.0%	✓ BEAT
Q2 2022	May 16, 2022	$2.10	$4.90	+133.3%	✓ BEAT
Q1 2022	Mar 31, 2022	$0.04	$0.06	+33.3%	✓ BEAT
Q4 2021	Nov 22, 2021	$4.20	$2.10	-50.0%	✗ MISS
Q3 2021	Sep 30, 2021	—	$-5.81	—	—
Q2 2021	May 17, 2021	$-0.06	$-4.38	-7198.2%	✗ MISS
Q2 2021	Apr 15, 2021	—	$11.19	—	—
Q4 2020	Nov 9, 2020	$2.80	$6.99	+149.6%	✓ BEAT
Q3 2020	Aug 17, 2020	$4.90	$9.09	+85.5%	✓ BEAT
Q2 2020	May 18, 2020	$3.50	$6.99	+99.7%	✓ BEAT
Q1 2020	Mar 30, 2020	$2.56	$5.59	+118.4%	✓ BEAT
Q4 2019	Nov 12, 2019	$4.20	$7.69	+83.1%	✓ BEAT

Frequently Asked Questions about ADMP

What is ADMP's current stock price?

Adamis Pharmaceuticals Corporation (ADMP) is currently trading at $0.78 per share. The stock has moved +0.85% today.

What is the analyst price target for ADMP?

No analyst price targets are currently available for this stock.

What sector is Adamis Pharmaceuticals Corporation in?

Adamis Pharmaceuticals Corporation operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company is traded on the NASDAQ exchange.

What is ADMP's market cap?

Adamis Pharmaceuticals Corporation has a market capitalization of $0.01 billion, making it a small-cap company.

Does ADMP pay dividends?

No, Adamis Pharmaceuticals Corporation does not currently pay a dividend to shareholders.